UK gets reduced Section 232 pharma tariff treatment, but reports differ on the rate

The United Kingdom has secured reduced treatment under the U.S. Section 232 pharmaceutical tariffs, according to a trade advisory dated Aug. 4, 2026, which states that the UK receives a 0 percent Section 232 tariff on pharmaceuticals as of July 31, 2026 ^[1]. Reports of the exact UK rate do not agree, and the terms of the arrangement have not been disclosed.

The framework itself came from an April 2, 2026 proclamation. It imposes a 100 percent duty on patented pharmaceutical articles — drugs and biologics listed in the FDA's Orange Book or Purple Book — and on their active ingredients and key starting materials ^[1][2]. The duty took effect at 12:01 a.m. Eastern time on July 31, 2026 for most companies ^[1]. Products of Japan, the European Union, Korea, Switzerland and Liechtenstein carry a 15 percent rate instead of 100 percent ^[1][2]. The UK is not listed among those 15 percent jurisdictions in either account ^[1][2].

Reports on the UK rate differ in three ways. An April 3 breakdown assigned UK products a 10 percent rate under tariff heading 9903.04.63 ^[1]. An April 7 legal alert described UK products as carrying a 10 percentage-point addition on top of the general 100 percent rate, "reducible to zero to the extent required by a future bilateral pharmaceutical pricing agreement" ^[2]. The later item, dated Aug. 4, 2026, states the UK receives 0 percent ^[1]. Nothing in these accounts describes when the UK arrangement was concluded, what products it covers, or whether it is final.

Other routes to a lower rate exist. Imports for companies identified by the Secretary are free of additional duty before 12:01 a.m. Eastern time on Sept. 29, 2026 under heading 9903.04.61 ^[1]; a separate account says that delay covers 17 named companies and that tariffs for companies listed in one annex begin Sept. 29, 2026 ^[2]. Companies that entered a most-favored-nation pharmaceutical pricing agreement with the Department of Health and Human Services pay 0 percent under heading 9903.04.65 ^[1]. Companies with a Commerce-approved onshoring plan pay an additional 20 percent through April 2, 2030, and those that also hold an MFN pricing agreement pay no additional tariff until Jan. 20, 2029, including the 13 companies listed in an annex ^[1][2].

Exemptions are broad. Generic pharmaceuticals and biosimilars, U.S.-origin pharmaceutical products and their ingredients, and products in certain tariff codes are excluded ^[1][2]. So are drugs designated as orphan products under the Orphan Drug Act, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody drug conjugates, medical countermeasures for chemical, biological, radiological and nuclear threats, animal health products, and other specialty products the Secretary of Commerce identifies later ^[1][2]. Drawback remains available on duties paid, and goods entering a U.S. foreign trade zone must generally be admitted as privileged foreign status ^[1][2].

Why it matters for patients

The tariffs apply to imported patented drugs and their ingredients, so the products in scope are branded medicines that cross the border — not generics or biosimilars, which are excluded for now ^[1][2]. Whether any of this changes what a U.S. patient pays has not been reported. U.S. list prices, insurance negotiations and copays are set through other mechanisms, and none of these accounts describes a tariff-driven price change for any specific medicine.

It also has not been reported which GLP-1 products are imported rather than made in the United States, or whether the companies that make them hold the pricing agreements that carry a 0 percent rate ^[1]. The most-favored-nation route is worth understanding because it ties tariff relief to what companies charge U.S. payers: a company reaches 0 percent only by signing a pricing agreement with HHS ^[1], and one account says companies with an approved onshoring plan keep a 20 percent charge until 2030 unless they also sign such an agreement ^[2]. That makes the duty a lever on U.S. pricing, not only a border tax.

What happens next

Sept. 29, 2026: the no-additional-duty period ends for companies identified in the annexes, and tariffs for those companies begin ^[1][2].

Within one year of the April 2, 2026 proclamation: the Commerce Department must advise the President on whether to extend Section 232 tariffs to generic pharmaceuticals and their ingredients ^[2].

April 2, 2030: the 20 percent rate tied to approved onshoring plans runs to this date, while the exemption for companies that also hold an MFN pricing agreement runs until Jan. 20, 2029 ^[2].

No public update has been reported on the 90-day negotiation report Commerce was instructed to deliver after the proclamation, or on whether a bilateral pricing agreement with the UK will be concluded. If one is reached, the UK rate could change again ^[2].